-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2025-522542-40-00
5
Acute Ischemic Stroke
-
2023-503523-25-00
4
2024-02-29
Non-small cell lung cancer
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2024-515023-11-00
5
2026-01-22
Metastatic Clear Cell Renal Cell Carcinoma
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2024-519945-31-00
5
2025-08-21
Type 1 Diabetes
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
-
2024-513869-39-00
5
2025-06-27
Obstructive Cardiomyopathy, Hypertrophic
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2023-507776-42-00
5
2024-11-14
Non-small cell lung cancer
-
2023-508613-17-00
5
2024-05-29
Neoplasms, Head and Neck
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2025-521096-31-00
5
2025-10-02
Chronic Hepatitis C Virus (HCV) Infection
-
2022-501483-18-00
10
2025-03-28
Advanced Non-Small Cell Lung Cancer
-
2024-516213-20-00
5
2025-03-25
Psoriatic arthritis
-
2023-504753-12-00
5
2024-10-01
Lung Cancer, Non-Small Cell